Chemotherapy of esophageal cancer.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008935:Mitoguazone / Q000008:administration & dosage; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011182:Postoperative Care; D011300:Preoperative Care; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014751:Vindesine
D000970:Antineoplastic Agents; D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D014747:Vinblastine; D005047:Etoposide; D008130:Lomustine; D004317:Doxorubicin; D008935:Mitoguazone; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil; D008727:Methotrexate